The dry roots of Salvia miltiorrhiza, also called "Danshen" in Chinese, are a well-known traditional Chinese medicinal herb. Because of its better performance and fewer side effects confirmed during the long-time clinical use, Danshen is widely used in traditional Chinese medicinal preparations to treat a number of coronary heart diseases, especially angina pectoris and myocardial infarction. [1] [2] [3] [4] At present, a variety of Danshen products are commercially available, such as Fufang Danshen Tablets and Fufang Danshen Dripping pills, which are the two most commonly used ones in China and these have been officially listed in the Chinese Pharmacopoeia 2005.
According to their chemical structures, the major bioactive constituents in S. miltiorrhiza BUNGE can be classified into two groups: the tanshinone compounds, which belong to a group of lipid-soluble diterpenoids, and water-soluble polyphenolic compounds. 6) The major lipophilic components are cryptotanshinone, tanshinone I and tanshinone IIA (TSIIA). Pharmacological tests have revealed that TSIIA possesses a variety of pharmacological activities including antioxidant effects, 7) prevention of angina pectoris and myocardial infarction, 8) as well as antineoplastic, 9) anticancer, 10, 11) and anti-inflammatory effects. 12) The major hydrophilic components include danshensu, protocatechuic aldehyde and salvianolic acid B (Sal B). Sal B is the most common component in the Salvia species and the most abundant in their aqueous extracts. 13, 14) Different studies have shown that Sal B has a variety of biological activities including anti-oxidation, 15, 16) antifibrotic, 17) and myocardial salvage effects 18) ; it also prevents hepatitis and uremia, 19) and improves blood circulation and renal function. [20] [21] [22] [23] [24] [25] Considering their prominent pharmacological activities and high content in Danshen, both TSIIA and Sal B have been selected as marker components for the quality control of Danshen and many other medicinal preparations containing Danshen in the 2005 edition of Chinese Pharmacopoeia. 6, 12, 26) The chemical structures of TanIIA and Sal B are shown in Fig. 1 .
Recently, Song et al. 27) showed that the pharmacokinetics of cryptotanshinone and TSIIA in rats after oral intra-gavage of an extract of tanshinones was significantly affected by the co-present tanshinones. Also, Sal B had a lower effective concentration in vitro angiogenesis study than the crude extract. 28) In clinical practice, most Danshen products used consist of tanshinone and polyphenolic extracts at the same time.
5) However, there have been no reports of pharmacokinetic interactions between tanshinones and polyphenolic extracts of S. miltiorrhiza BUNGE in vivo.
To date, several methods have been established for the de-termination of TSIIA in rat plasma. 12, 29, 30) Some HPLC methods have also been described for the determination of Sal B in rat plasma. [31] [32] [33] These methods only determine TSIIA and Sal B, separately and it is not possible to simultaneously determine both of them in vivo. The purpose of this study was to investigate the pharmacokinetic interactions between tanshinones and polyphenolic extracts of S. miltiorrhiza BUNGE in rats after intravenous administration by simultaneously monitoring the two marker components of Danshen-TSIIA and Sal B.
MATERIALS AND METHODS

Materials
The tanshinones extract was obtained by supercritical CO 2 fluid extraction of Salvia miltinorrhiza BUNGE (Guangzhou, China), in which the content of TSIIA was determined by HPLC to be 40.1%. The residue of Salvia miltinorrhiza BUNGE was extracted at pH 1-2 with deionized water and further purified on an AB-8 absorbent resin (Bengbu Tianxing Resin Co., Ltd., Anhui, China). The eluate was concentrated under reduced pressure with a Model RE-3000 rotary evaporator (Shanghai Yarong Biochemistry Instrument Co., Ltd., Shanghai, China) and freeze-dried in an ZYZLA ® FDU-1100/DRC-1000 freeze drier (Tokyo Rikakikai Co., Ltd., Tokyo, Japan) to obtain a purified polyphenolic extract, with a Sal B content of 61.2%.
Acetonitrile and formic acid (HPLC grade) were supplied by Dikma (Richmond Hill, NY, U.S.A. Preparation of Tanshinones Extract-Loaded Emulsion and Polyphenolic Extract Solution Soybean oil and MCT were mixed under stirring at 70°C to obtain the oil phase while F68, sodium oleate, and glycerol were dispersed in water for injection by stirring at 75°C to obtain a water phase. The oil phase was added to the water phase and mixed using a high-shear mixer at 8000 rpm to prepare a coarse emulsion, and then the tanshinones extract was added, with further stirring until a primary emulsion was obtained. After adjusting the pH to approx. 7.0 with 0.1 mol/l HCl or NaOH solution, the primary emulsion was passed through a high pressure homogenizer (Niro Soavi NS10012k, Niro Soavi S.p.A., Via M. Da Erba, Italy). Finally, the preparation was gassed with N 2 and sealed in 10 ml glass bottles followed by autoclaving for 30 min at 100°C.
The polyphenolic extract solution was prepared by dissolving the polyphenolic extract in deionized water, adding glycerol for isoosmotic adjustment, and then adjusting the pH to approx. 7.0 with 0.1 mol/l HCl or NaOH solution. Animal Experiments and Drug Administration Fiftyfour male Wistar rats (8 weeks old, 200Ϯ20 g) were obtained from the Laboratory Animal Center of Shenyang Pharmaceutical University. The experimental protocol was approved by the University Ethics Committee for the use of experimental animals and conformed to the Guide for Care and Use of Laboratory Animals. Rats were housed in groups of eighteen with a 12-h light/dark cycle at a temperature of 22Ϯ3°C, and relative humidity of 45-60%, for one week. Before the day of administration, the rats were fasted for 12 h but were allowed water ad libitum.
Animal experiments were conducted on three consecutive days. On the first day, eighteen rats were divided into three equal groups. Medium dosed group I: 10 mg/kg tanshinones extract-loaded emulsion (equivalent to 4.0 mg/kg TSIIA), medium dosed group II: 100 mg/kg polyphenolic extract solution (equivalent to 61.2 mg/kg Sal B) and medium dosed group III: mixed extracts-loaded emulsion (containing 10 mg/kg tanshinones extract and 100 mg/kg polyphenolic extract, equivalent to 4.0 mg/kg TSIIA and 61.2 mg/kg Sal B), which were given to rats by intravenous injection via the femoral vein. The tanshinones extract-loaded emulsion and polyphenolic extract solution were prepared by the method described above. The mixed extracts-loaded emulsion was prepared similarly with a tanshinones extract-loaded emulsion by combining both the tanshinones and polyphenolic extracts.
The low dose and high dose groups were also prepared in a similar manner to the medium dose group on the second and third days, respectively. The dosage of the low dose group was half that of the medium dose group, while that of the high dose group was twice the dosage of the medium dose group.
Blood samples (250 ml) were collected from each rat into heparinized Eppendorf tubes (2.0 ml) by puncture of the retro-orbital sinus. This was performed at 0 (predose), 0.083, 0.167, 0.250, 0.333, 0.500, 0.750, 1.0, 1.5, 2.0, 3.0 4.0, 6.0 and 12.0 h after intravenous administration. Then, as soon as possible, the heparinized blood was centrifuged for 10 min at 2000ϫg, and the plasma obtained was stored frozen at Ϫ20°C until analysis.
UPLC/MS/MS Analysis Frozen plasma samples were thawed at room temperature and vortexed to achieve a good mixing prior to precipitation. Then, to a 100 ml aliquot of plasma in a 2.0 ml Eppendorf tube, 50 ml of the IS and 250 ml acetonitrile was added. The mixture was vortexed for 5.0 min and then centrifuged at 10000 rpm for 5 min in a FULGOR GL-20B refrigerated centrifuge (Shanghai, China) which was kept at 4°C. Then, a 5.0 ml aliquot of the clean supernatant was injected into the UPLC/MS/MS system for analysis.
Chromatography was performed using an ACQUITY TM UPLC system (Waters Corp., Milford, MA, U.S.A.) with a conditioned autosampler at 4°C. The separation was carried out on an ACQUITY UPLC TM BEH C 18 column (50 mmϫ2.1 mm i.d., 1.7 mm; Waters Corp., Milford, MA, U.S.A.) maintained at a temperature of 35°C. The analysis was carried out by gradient elution using (A) acetonitrile and (B) water (containing 0.1% formic acid) as the mobile phase.
The gradient started at 10% A and increased linearly to 80% A in 1.0 min, maintained at 80% for 1.0 min and then returned to the initial condition for another 1.0 min of re-equilibration. The flow rate was set at 0.35 ml/min. The injection volume was 5 ml using the partial loop mode for sample injection. A Waters ACQUITY TM TQD triple-quadrupole tandem mass spectrometer (Waters Corp., Manchester, U.K.) was interfaced to the UPLC system via electrospray ionization (ESI) interface. The capillary, extractor and RF voltages were set at 2.3 kV, 2.0 V and 0.7 V, respectively. The temperature of the source and desolvation was set at 80 and 400°C, respectively. Nitrogen was used as the desolvation gas (500 l/h) and cone gas (50 l/h) while argon was used as the collision gas at a flow rate of 0.15 ml/min (approx.
2.81ϫ10
Ϫ3 mbar). The multiple reaction monitoring (MRM) mode was used for quantification. The optimized conditions of MRM fragmentation transitions are listed in Table 1 . All data collected in the centroid mode were acquired using Masslynx TM NT4.1 software (Waters Corp., Milford, MA, U.S.A.). Post-acquisition quantitative analyses were performed using a QuanLynx TM program (Waters Corp., Milford, MA, U.S.A.).
Typical MRM chromatograms of TSIIA and Sal B are shown in Fig. 2 . Three channels were used for recording the response, channel I for TSIIA with a typical retention time of 1.97 min, channel II for IS with a typical retention time of 1.11 min, and channel III for Sal B with a typical retention time of 0.94 min. TSIIA, Sal B and I.S. were well separated with excellent peak shapes, and no interfering peaks were observed in the blank plasma and in all samples tested. The lower limit of quantitation (LLOQ) for determination of TSIIA and Sal B in plasma, defined as the lowest concentration analyzed with an accuracy within Ϯ20% and a precision Յ20%, were 0.90 ng/ml and 0.15 mg/ml, respectively. The coefficient of variation was less than 9.87% for TSIIA and less than 9.75% for Sal B.
Pharmacokinetic Study The pharmacokinetic parameters were calculated using DAS (drug and statistics) version 2.0 software (Mathematical Pharmacology Professional Committee of China, Shanghai, China) using non-compartmental pharmacokinetic methods. The maximum plasma concentration (C 0.083 h ) was directly obtained from the observed concentration-time data (0.083 h). The elimination rate constant (k e ) was calculated by linear regression of the terminal points of the semi-log plot of plasma concentration against time. The elimination half-life (t 1/2 ) was calculated using the formula t 1/2 ϭ0.693/k e . The area under the plasma concentration-time curve (AUC 0-t ) to the last measurable plasma concentration (C t ) was calculated by the linear trapezoidal rule. AUC 0-∞ was obtained from AUC 0-t ϩC t /k e , where C t was the last measurable drug concentration. Total plasma clearance (CL t ) was calculated as Dose/AUC 0-∞ .
Statistical Analysis
The data are presented as mean with standard error (S.E.) values for the individual groups. An unpaired Student's t-test was used to determine any significant differences. Differences were considered to be significant at level of pϽ0.05.
RESULTS
The mean plasma concentration-time profiles of TSIIA in the groups after intravenous administration of tanshinones extract-loaded emulsion and mixed extracts-loaded emulsion are shown in Fig. 3 . The mean pharmacokinetic parameters of TSIIA are listed in Table 2 . Significant differences in the total plasma clearance (CL t ) and C 0.083 h were found between the tanshinones extract-loaded emulsion groups and the mixed extracts-loaded emulsion groups for each of the dose levels (pϽ0.01). The total plasma clearance (CL t ) was signif- icantly lower in the mixed extracts-loaded emulsion groups (pϽ0.01), while C 0.083 h was significantly higher in the mixed extracts-loaded emulsion groups (pϽ0.01). As far as the AUC was concerned, the AUC of TSIIA in the medium and low dose group III was approximately 2 times (pϽ0.05) higher than in the medium and low dose groups I, however, the AUC of the high dose group III was found to be 3595.9Ϯ579.9 mg l Ϫ1 h
Ϫ1
, which was significantly higher (about 14 times) than that of the matched group (pϽ0.01).
With regard to elimination, the terminal elimination halflife (t 1/2 ) of the mixed extracts-loaded emulsion group was increased compared with that of the equivalent tanshinones extract-loaded emulsion group. Although the terminal elimination half-life (t 1/2 ) increased by 38% in the low dose group and by 46% in the medium dose group, the difference was not statistically significant (pϾ0.05). However, there was a significant difference between the two high dose groups (increase of 120%, pϽ0.05).
Sal B pharmacokinetics was estimated following intravenous administration of three dose levels of polyphenolic extract solution and mixed extracts-loaded emulsion, separately. The mean plasma Sal B concentration-time profiles are shown in Fig. 3 , and the mean pharmacokinetic parameters are given in Table 3 .
It was found that the pharmacokinetic parameters (C 0.083 h , CL and AUC) in the mixed extracts-loaded emulsion groups were significantly different from the polyphenolic extract solution groups for each dose level (pϽ0.01). A marked increase (pϽ0.01) was observed in both the AUC and C 0.083 h in rats given the mixed extracts-loaded emulsion compared with the rats receiving the polyphenolic extract solution alone. However, the total plasma clearance (CL t ) of the mixed extracts-loaded emulsion group was significantly reduced compared with that of the polyphenolic extract solution group (pϽ0.01). As for t 1/2 , there was no significant difference between corresponding dose levels. 
DISCUSSION
Various factors might affect the plasma concentration profiles of TSIIA under the experiment condition employed in our study. However, there is no significant difference of pharmacokinetic profiles between emulsion and non-emulsive solution under our experiment condition. Seki et al. 34) Reported at "Lipid microsphere (LM, dϭ200-300 nm) easily entered reticuloendothelial systems, such as the liver, and was rapidly cleared from the circulation. While, Lipid nano-shere (LNS, dϭ25-50 nm) showed much higher plasma levels after intravenous administration to rats." This was also confirmed by Tokino et al. 35) In our previous study, [36] [37] [38] no significant difference of pharmacokinetics was observed either. The emulsion we prepared in our study also called Lipid microshere, the diameter of which is ca. 250 nm. Thus, in this case, the plasma TSIIA and Sal B profiles do not depend on the pharmacokinetics of the emulsion particles.
Previous investigations have indicated that the concentration of tanshinones in bile was much higher than that in plasma and in urine, suggesting that the tanshinones are mainly metabolized in liver. 39) This was confirmed by administering pure TSIIA. Tanshinone IIB, 3a-hydroxytanshinone IIA and przewaquinone A were identified in the bile samples and these were the three hydroxylated metabolites of TSIIA. 40) Recent research indicated that TSIIA may posses complex inhibiting and inducing characteristics as far as the CYP450 enzyme is concerned. It has been shown that CYP 2C19 and CYP 3A1 are involved in the metabolism of TSIIA and CYP 2D6 also contributes to metabolism to some extent. 41) Their selective inhibitors may potentially inhibit the metabolism of TSIIA and increase the systemic exposure of TSIIA.
Chen et al. 31) reported that, after intravenous administration of 100 mg/kg Sal B, the bile-to-blood distribution (AUC bile /AUC blood ) was 1.55Ϯ0.21. Sal B was rapidly and readily excreted into the bile, thus producing bile concentrations higher than those in blood. Furthermore, the distribution ratio of AUC bile /AUC blood of Sal B suggested that the hepatobiliary elimination of Sal B was predominant. Zhang et al. 42) showed that Sal B was rapidly and completely taken up by hepatocytes, where most of the Sal B was methylated, and that the methylated metabolites were excreted into bile, probably through a transporter-dependent mechanism. In addition, all the methylated metabolites were characterized as meta-O-methylated products. COMT (catechol O-methyltransferase) seemed to be responsible for the metabolic transformation of Sal B.
As shown in Tables 2 and 3 39, 40) TSIIA is a dehydrogenated metabolite of cryptotanshinone. Thus, The TSIIA profile may be affected by cryptotanshinone being metabolized to TSIIA. When mixed extracts-loaded emulsion was administrated to rats, not only was there competitive metabolism of TSIIA, but also much of the cryptotanshinone was metabolized to TSIIA. There is another possibility that Sal B altered the TSIIA profile by accelerating the TSIIA generating process from cryptotanshinone. All resulted in a rapid increase in the original plasma concentration of TSIIA over a short time, especially for the high dose group.
CONCLUSION
The pharmacokinetic interaction between tanshinones and polyphenolic extracts of S. miltiorrhiza BUNGE in rats was investigated. It was found that an interaction between them occurred after intravenous administration in rats, which resulted in the reduced elimination of both TSIIA and Sal B. The mechanism of this interaction needs further study. A better understanding of the herb-drug interaction requires a great deal of work further in order to minimize or avoid therapeutic failures. And it may provide useful information to avoid unexpected increase of the plasma drug concentration in the clinical practice. 
